Principal Financial Group Inc Fulcrum Therapeutics, Inc. Transaction History

Principal Financial Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 29, 2024	SELL	$6.7 - $12.0 $11,792 - $21,120	-1,760 Reduced 9.78%	16,233 $153,000
Q4 2023 Feb 07, 2024	SELL	$3.18 - $6.86 $2,404 - $5,186	-756 Reduced 4.03%	17,993 $121,000
Q3 2023 Nov 02, 2023	BUY	$3.25 - $6.08 $5,482 - $10,256	1,687 Added 9.89%	18,749 $83,000
Q2 2023 Aug 07, 2023	BUY	$2.26 - $3.8 $4,000 - $6,726	1,770 Added 11.57%	17,062 $56,000
Q1 2023 May 09, 2023	BUY	$2.83 - $13.99 $6,992 - $34,569	2,471 Added 19.27%	15,292 $43,000
Q4 2022 Feb 09, 2023	BUY	$5.01 - $8.35 $64,233 - $107,055	12,821 New	12,821 $93,000

150

52.2M

6.91M

1.9M

Ticker FULC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,038,900
Market Cap $156M
Description
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.